https://www.selleckchem.com/pr....oducts/Azacitidine(V
96, 95% confidence interval [CI]=1.3-6.9; p= 0.012), and tumor histologic type (clear cell/endometrioid vs. mucinous; OR32.8, 95% CI=6.9-154.8, p 0.001; clear cell/endometrioid vs. serous OR 48.1, 95% CI=8.8-261.8, p 0.001) were independent risk factors for an upgrade of the permanent diagnosis from a BOT to ovarian carcinoma. An elevated CA-125 level (over 136 U/mL) and tumor histologic type (clear cell and endometrioid subtypes) were associated with an upgrade in the diagnosis of ovarian tumor from a BOT on frozen
Like
Comment
Share
